Organigram Reports 262% Higher Quarterly Net Loss YoY, Makes Progress In International Markets
Organigram Reports 262% Higher Quarterly Net Loss YoY, Makes Progress In International Markets
Canadian cannabis company Organigram Holdings Inc.(NASDAQ:OGI) (TSX:OGI) reported its financial results Tuesday for the second quarter that ended March 31, 2024, revealing net revenue of CA$37.63 million ($27.53 million), compared to CA$39.5 million in the same period of last year.
加拿大大麻公司Organigram Holdings Inc.(纳斯达克股票代码:OGI)(多伦多证券交易所股票代码:OGI)周二公布了截至2024年3月31日的第二季度财务业绩,净收入为3763万加元(合2753万美元),而去年同期为3,950万加元。
"We are pleased with our performance against the strategic priorities we laid out at the beginning of Fiscal 2024," stated CEO Beena Goldenberg. "Organigram is now the only licensed producer among the top three licensed producers in Canada with significant cash, negligible debt, and sizeable funds earmarked for strategic international investment. We have also made solid progress toward our goal of diversifying our exposure to international markets through our Jupiter fund and increasing our customer base abroad. Domestically, we grew our market share throughout Q2 Fiscal 2024 and we remain focused on driving additional gains in the back half of Fiscal 2024 by expanding distribution, introducing new products, and executing high-impact retail campaigns."
首席执行官比娜·戈登伯格表示:“我们对我们在2024财年初制定的战略优先事项方面的表现感到满意。”“Organigram现在是加拿大前三大持牌生产商中唯一一家拥有大量现金、微不足道的债务和大量专用于战略国际投资的资金的持牌生产商。我们在实现通过木星基金分散国际市场敞口和增加海外客户群的目标方面也取得了稳步进展。在国内,我们在2024财年第二季度增长了市场份额,我们将继续专注于通过扩大分销、推出新产品和开展高影响力的零售活动来推动2024财年后半年的额外收益。”
More about investments and financial data from the industry you can hear at the 19th Benzinga Cannabis Capital Conference in Chicago this October 8-9. Engage with top executives, investors, policymakers, and advocates to explore the industry's future. Secure your tickets now before prices increase by following this link.
您可以在10月8日至9日在芝加哥举行的第19届Benzinga大麻资本会议上听到有关该行业投资和财务数据的更多信息。与高层管理人员、投资者、政策制定者和倡导者互动,探索该行业的未来。在价格上涨之前,立即通过以下方式保护您的门票 这个链接。
Fiscal Q2 Financial Summary
第二财季财务摘要
- Net loss amounted to CA$27.08 million, a 262% change from net loss of CA$7.49 million in the same period of 2023. The increase in net loss from the comparative period, the company attributed primarily to lower unrealized gain on changes in the fair value of biological assets and change in fair value of derivative liabilities of $12.5 million.
- Adjusted EBITDA was a loss of CA$1.05 million, versus an adjusted EBITDA gain of CA$5.65 million in the corresponding period of last year.
- The gross margin before fair value changes to biological assets, inventories sold, and other charges was CA$11.26 million, which compares to a gross margin of CA$9.85 million in the second fiscal quarter of 2023.
- Selling (including marketing), general & administrative expenses grew 25% year-over-year to CA$20.16 million.
- Cost of sales decreased to CA$26.4 million, from CA$29.6 million in the same period of 2023, primarily due to higher inventory provisions in the second fiscal quarter of 2023 of CA$3.2 million related to net realizable value adjustments of inventories
- On March 31, 2024, the company had cash (restricted & unrestricted) of $83.6 million.
- 净亏损为2708万加元,较2023年同期的749万加元净亏损增长262%。与比较期相比,该公司净亏损的增加主要归因于生物资产公允价值变动的未实现收益减少以及衍生负债公允价值变动1,250万美元。
- 调整后的息税折旧摊销前利润为亏损105万加元,而去年同期调整后的息税折旧摊销前利润收益为565万加元。
- 扣除生物资产、出售库存和其他费用的公允价值变动前的毛利率为1126万加元,而2023年第二财季的毛利率为985万加元。
- 销售(包括营销)、一般和管理费用同比增长25%,达到2,016万加元。
- 销售成本从2023年同期的2960万加元降至2640万加元,这主要是由于2023年第二财季与库存可变现净值调整相关的库存准备金增加了320万加元
- 2024年3月31日,该公司的现金(限制性和非限制性)为8,360万美元。
OGI Price Action
OGI 价格走势
Organigram shares traded flat at $1.84 per share during Tuesday's pre-market session.
在周二的盘前交易中,Organigram股价持平至每股1.84美元。
Photo: Courtesy of ShutterstockProfessional via Shutterstock
照片:由 ShutterstockProfessional 通过 Shutterstock 提供